BR0117014A - Método para a proliferação de células diferenciadas terminais, vetor recombinante, célula ou tecido de mamìfero, composição farmacêutica para a proliferação de células ou tecidos diferenciados terminais, e, método para tratar cardiopatia em um paciente humano - Google Patents

Método para a proliferação de células diferenciadas terminais, vetor recombinante, célula ou tecido de mamìfero, composição farmacêutica para a proliferação de células ou tecidos diferenciados terminais, e, método para tratar cardiopatia em um paciente humano

Info

Publication number
BR0117014A
BR0117014A BR0117014-7A BR0117014A BR0117014A BR 0117014 A BR0117014 A BR 0117014A BR 0117014 A BR0117014 A BR 0117014A BR 0117014 A BR0117014 A BR 0117014A
Authority
BR
Brazil
Prior art keywords
differentiated cells
cyclin
proliferation
terminal differentiated
cells
Prior art date
Application number
BR0117014-7A
Other languages
English (en)
Inventor
Masaaki Ikeda
Mimi Adachi
Original Assignee
Masaaki Ikeda
Mimi Adachi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Masaaki Ikeda, Mimi Adachi filed Critical Masaaki Ikeda
Publication of BR0117014A publication Critical patent/BR0117014A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO PARA A PROLIFERAçãO DE CéLULAS DIFERENCIADAS TERMINAIS, VETOR RECOMBINANTE, CéLULA OU TECIDO DE MAMìFERO, COMPOSIçãO FARMACêUTICA PARA A PROLIFERAçãO DE CéLULAS OU TECIDOS DIFERENCIADOS TERMINAIS, E, MéTODO PARA TRATAR CARDIOPATIA EM UM PACIENTE HUMANO". As células diferenciadas terminais são proliferadas pela transferência de uma ciclina e de uma quinase dependente de ciclina nos núcleos das células diferenciadas terminais e depois cultivando-se ou mantendo-se as células resultantes. Em particular, um método de proliferar as células diferenciadas terminais aplicáveis ao tratamento de doenças do coração, etc. pode ser fornecido pela adição de uma seq³ência de base que codifica um sinal de transporte nuclear a pelo menos um de um gene de ciclina e de um gene de quinase dependente de ciclina, transferindo-se estes genes em células diferenciadas terminais in vitro e depois cultivando-se as células ou transferindo-se os genes descritos acima em células diferenciadas terminais in vivo. A ciclina como descrita acima é uma ciclina que é capaz de ativar CDK4 ou CDK6, enquanto a quinase dependente de ciclina descrita acima é uma que é ativada pela ciclina do tipo D. Além disso, um vetor recombinante utilizável no método acima e os medicamentos contendo o mesmo são fornecidos.
BR0117014-7A 2001-05-17 2001-09-21 Método para a proliferação de células diferenciadas terminais, vetor recombinante, célula ou tecido de mamìfero, composição farmacêutica para a proliferação de células ou tecidos diferenciados terminais, e, método para tratar cardiopatia em um paciente humano BR0117014A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001148266 2001-05-17
PCT/JP2001/008208 WO2002095026A1 (fr) 2001-05-17 2001-09-21 Procede permettant de faire proliferer des cellules a differenciation terminal et vecteur de recombinaison pour la mise en oeuvre de ce procede

Publications (1)

Publication Number Publication Date
BR0117014A true BR0117014A (pt) 2004-04-20

Family

ID=18993622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0117014-7A BR0117014A (pt) 2001-05-17 2001-09-21 Método para a proliferação de células diferenciadas terminais, vetor recombinante, célula ou tecido de mamìfero, composição farmacêutica para a proliferação de células ou tecidos diferenciados terminais, e, método para tratar cardiopatia em um paciente humano

Country Status (4)

Country Link
JP (1) JP4499994B2 (pt)
BR (1) BR0117014A (pt)
CA (1) CA2447703C (pt)
WO (1) WO2002095026A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014038653A1 (ja) * 2012-09-07 2016-08-12 国立大学法人京都大学 腎臓由来体性幹細胞の製造方法
JPWO2014038655A1 (ja) * 2012-09-07 2016-08-12 国立大学法人京都大学 腸上皮由来体性幹細胞の製造方法
US10669596B2 (en) 2015-04-07 2020-06-02 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods for inducing cell division of postmitotic cells

Also Published As

Publication number Publication date
CA2447703C (en) 2011-04-19
WO2002095026A8 (fr) 2003-03-06
JP4499994B2 (ja) 2010-07-14
WO2002095026A1 (fr) 2002-11-28
CA2447703A1 (en) 2002-11-28
JPWO2002095026A1 (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
KR20080106332A (ko) 인간 배아 줄기 세포 및 그의 유도체를 포함하는 조성물, 그의 사용 방법 및 제조 방법
Kim et al. Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress
IL190542A0 (en) Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
Leung et al. Effects of far infrared rays on hydrogen peroxide-scavenging capacity
Tan et al. Response of the sensorimotor cortex of cerebral palsy rats receiving transplantation of vascular endothelial growth factor 165-transfected neural stem cells
CN109295001A (zh) 一种脐带间充质干细胞复合外泌体及其制备方法
Lu et al. MiR-26a inhibits myocardial cell apoptosis in rats with acute myocardial infarction through GSK-3β pathway.
BR0117014A (pt) Método para a proliferação de células diferenciadas terminais, vetor recombinante, célula ou tecido de mamìfero, composição farmacêutica para a proliferação de células ou tecidos diferenciados terminais, e, método para tratar cardiopatia em um paciente humano
CN109793913A (zh) 包含表皮生长因子的缓释膜敷料
ATE298256T1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
CN104152401A (zh) 一种适于中国人表皮黑素细胞体外培养的chmm1培养基
CN102342949B (zh) 根皮苷在制备治疗高尿酸血症药物中的应用
Caicedo et al. Advancing mitochondria as a therapeutic agent
CN103285379A (zh) Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途
Turi et al. Effect of heat on the microtubule disassembly and its relationship to body temperatures
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
Fazili et al. Therapeutic effects of in vivo-differentiated stem cell and Matricaria chamomilla L. Oil in diabetic rabbit
CN109908167A (zh) 蒙花苷在制备保护肾小管上皮细胞缺血再灌注损伤药物/药物组合物中的应用
Yuan et al. Mouse parabiosis model promotes recovery of lymphocytes in irradiated mice
CN104873493B (zh) 2‑羟基泽兰内酯在制备抗肿瘤药物中的应用
CN103330940B (zh) 联合制剂及其在制备非小细胞肺癌药物中的应用
ES2146348T3 (es) Cromanilsulfonil(tio)ureas sustituidas, procedimiento para su preparacion y su utilizacion en preparados farmaceuticos, asi como preparados farmaceuticos que las contienen.
WO2023184666A1 (zh) 多肽药物及凝胶制剂的应用
CN105942532A (zh) 一种增加骨密度的保健品及其制备方法
Péault New from old: recycling differentiated cells into regenerative cells using traditional Chinese medicine? A tribute to Professor Rongxiang Xu

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 10 (VIII), 18 (III) E 25 DA LPI.

B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.